Localized initiatives & global virtual institutes

1. Localized initiatives & global virtual institutes Stina Gestrelius Medicon Valley Academy Sweden-Denmark April 2005

2. Medicon Valley 3.2 million inhabitants 140.000 students 6.000 bio-R&D >100 medtech companies >100biotech companies >50 pharma companies CROs,service providers, investors 36.000 employees (29’+7’) 60 % of DK+Sbio/med. exports 26 hospitals 6 science parks 14 universities

3. Universities inØresund Region *Copenhagen University (35,000 students) *Danish Technical University *Danish Pharmaceutical University *Danish Veterinary &Agricultural University *Roskilde University Center Copenhagen Business School Copenhagen IT University Danish Educational University Danish Library University Danish Arts and Architecture School *Lund University(35,000 students) *Malmö University College *Swedish Agricultural University Kristianstad University College * Denotes bio/med/tech research

4. Number of publications and citations in biotech (1997-2001) PublicationsCitations Boston 37,000 185,000 Bay Area (US) 27,500 140,000 Paris 27,000 85,000 Medicon Valley 15,000 52,000 Cambridge area 15,000 51,000 Stockholm 14,000 49,000 Munich 12,000 25,000 The Boston Consulting Group, 2002 .

5. Medicon Valley Number of biotech publications Karolinska Institutet Stanford Oxford City University of London, 2004 Strategic Report

6. Scientific Excellence • Diabetes • Neuroscience • Oncology • Inflammation • Infection control • Stemcell research • Nanotechnology • Proteomics

7. Medicon Valley Blockbusters Cipramil (antidepressive) Lundbeck Turbuhaler (powder inhalator) AstraZeneca, Lund NovoPen (insulin) Novo Nordisk

8. Research infrastructure investments • SWEGENE(Lund) • Postgenomic RT Programme • inSouth Western Sweden • BMC(Lund) • Bio Medical Center • CRC(Malmö) • Clinical Research Center • BRIC(Copenhagen) • Biotech Research and Innovation Center Total investments 3-4 billion SEK

9. ESS? LUND North Campus Area Gambro Sony Ericsson Active Biotech Chemical Centre Ideon Science Park Cryo-EM Microarray Genomic Ecology University Hospital LTH Proteomics Astra Zeneca Transgenic core facility BMC School of Economics Bioinformatics MAX-lab 500 m

10. *85 enterprises in Symbion (+BRIC)*Main competences are IT and Biotechnology Bio:ACADIA, AH Diagnostics, Astion, A-Syntese, BioMonitor, Cartificial, Chempaq, Ciphergen, CMC, Colotech, CopyGene, Direct Haler, ENKAM, Evolva, Genesto, HemeBiotech, KLIFO, Leucotech, Lica, LivingCell, MedChem, NatImmune, Nordic Bone, Pipeline Biotech, Schafer, TAG, Topo Symbion Science Park Copenhagen .

11. Medicon Valley Academy Initiative 1995 from universities and big pharma companies 2000:Private membership based non profit organisation Universities, hospitals & companies (250 members) 2 nations – 2 systems

12. Founding members LU: Per Belfrage (chair) KU: Søren Buus Skåne: Ingvar Wiberg K Amt: Joost Nielsen H:S: Helle Ulrichsen Fredr Amt: Anders Kyst Elected Mikael Ørum, Ventac Partners Sibylle Moltzen Lenz, Lundbeck Børge Diderichsen, NovoNordisk Lars Hedbys, Synarc Lars-Erik Arvidsson, AstraZeneca Cristina Glad, BioInvent Sven Frøkjær, DFU Søren Brunak, DTU Mogens Pedersen, Coloplast

13. Cluster Dynamics Upstream Midstream Knowledge Creation Technology Transfer Patents & Proof of Concept Business Planning Licences Testing Incubation/ Research Parks Universities & Research Institutions Venture Capital Public & Private Job Creation Funding Conception Formation Industry R & D Regulatory Environment Collaboration/ Partnerships Industry Maturity Growth Partnerships Clinical Trials M&A Activity Regulatory Economics Approval of Scale Downstream IPOs /gazelles Product Pipeline Labour Market Clusters & Networks Commercialisation

16. Medicon Valley Academy PhD programme (12) PhD students co-financed between companies and HUR/Region Skåne POST-DOC programme (9) • system biology • nanobiotechnology • 3D-modelling of molecular structures Cooperation between Ø-forsk, Øresund IT Academy andMedicon Valley Academy .

17. Bioinformatics • Biostatistics • Children and Diabetes • 3D-modelling of Proteins • Food versus Drugs (2) • Hospital laboratory of the future • Infectious diseases • Inflammation • IT-competent hospitals • Medical Imaging (2) • Nanobiotechnology • Neuroscience • Oncology • Point-of-care testing • Proteomics (2) • Stem cells therapeutic perspectives • Therapeutic medical devices

18. MVA Networks • Biostatistics • Business & Start-ups • Cancer • Diabetes • Drug Development • Food versus Drugs • Hospital Management • Human Resources • Hepatocyte User Group • Mass Spectroscopy • Technology Transfer

19. Strategic Report on Research in prep. Future research strategies and implications for Medicon Valley Copenhagen 30 March 2005 Bertil Andersson, European Science Foundation, Strasbourg Bruno Hansen, Danish Council for Research Policy, Copenhagen Staffan Normark, Swedish Foundation for Strategic Research, Stockholm Kristian Helin, Biotech Research & Innovation Center (BRIC), Copenhagen Other: Danish governmental declaration Feb 2005 Swedish research bill March 2005 Six Countries Programme Conference Etc.

20. Medicon Valley (2002) Karolinska Institutet (2003) Oxford University (2003) Stanford University (2002) INPUT Research spend per year (mill. €) 300 300 200-250 400 OUTPUT Publications 3200 2800 1900 2000 Invention disclosures 180 100 150 315 Commercialization of public research From BioScience to New Jobs in Medicon Valley - A Medicon Valley Academy Strategic Report

21. MVA STRATEGIC REPORTS Innovation Report 2004 Recommendations to improve the competitiveness of Medicon Valley • More commercial know-how into Technology Transfer Organisations • 2) Regional TTO cooperation (!) • 3) Funding for Proof-of-Concept studies • 4) Seed investments across Øresund (!) • 5) Tax incentives for the Young Biotech Industry From BioScience to New Jobs in Medicon Valley - A Medicon Valley Academy Strategic Report

22. Bioneer BKG Pharma Cytotrack DanChip Dermagen Dermalcol Essentys Medical Prognosis Inst Micromorph Neobiotics Novosense Oncore Therapeutics PHI Picology Plug-in Medical Protista Biotechnology Quantibact StratoSphere Pharma VibroSense Dynamics New bio/med-tech companies in 2004 Retrospective 125 new companies since 1997 Alt.venture capital, survival rates, IPOs etc.

23. Regional Guides • Patent Guide (2003) • Financing Guide (2004) • Drug Development Guide (2005)

25. Medicon Valley Academy Øresund IT Academy Øresund Food Network Øresund Environment ØresundLogistics Øresund Design Øresund Nano

26. Development over time Prep. InterReg project Membership organisation

27. Nordic Research & Innovation Aims for borderless systems within the Nordic countries

28. ScanBalt: Network of Networks • PLUS: • BioTop (Berlin) • BioMoBil (Gdansk) • Ebio (Tallinn-Tartu) • Latvia • St. Petersburg Sunrise Valley

29. ”I think the UK and this region are perfect partners and I would like to see even greater cooperation. I am, therefore, delighted to announce today the establishment of the UK-MVA Challenge Programme. This initiative aims to encourage and facilitate greater co-operation between the UK and the Öresund region in core biotechnology areas such as research and industry. The Challenge Programme seeks to develop world class biotechnology. ..” Lord Sainsbury, UK Minister of Research and Innovation (Oct. 2004)

30. Changed dynamics • Regional integration Denmark - Sweden • Researchers/ infrastructure /tech transfer/ investments • Sectorial integration Academia- Hospital- Industry • Increased research funding (regional, Nordic, EC) • Increased awareness of research & innovation

31. Changed dynamics • Increased investments, seed and venture capital for start-up companies (E&Y 2004) • New companies and knowledge intensive jobs • Increased internationalization incl.regional exchange with the UK • International companies established in the region (e.g. Biogen Idec)